Dr. Murali Prahlad, President and CEO of Iridia, Inc.

Dr. Murali Prahlad, President and CEO of Iridia, Inc.

Dr. Prahalad currently is the President and CEO of Iridia, Inc. (Iridia),
a venture backed company focused on the use of synthetic DNA as a
next generation medium for data storage.

Dr. Prahalad began his life sciences career at Sequenom, Inc., a San Diego based genomics company and pioneer in non-invasive prenatal diagnostics. He went on to hold various roles at Life Technologies Corporation, a global leader in reagents and instruments for biomedical research. His final role at Life Technologies was VP, Corporate Strategy which culminated in the strategic sale of Life Technologies to ThermoFisher Scientific (NYSE: TMO) in 2013 for $15.5B. Prior to Iridia, Dr. Prahalad was President and CEO of Epic Sciences (Epic), a company dedicated to the personalization of cancer care through the development of blood- based tests that predict drug response and extend life.

Dr. Prahalad received his B.Sc. with Honors from the University of Michigan in 1992. He went on to receive his Masters in Medical Sciences and Doctorate in Biochemistry and Molecular Pharmacology from Harvard University in 1995 and 1998, respectively.